BMC Proceedings

Poster presentation

A multiparameter panel for the staging of human African trypanosomiasis patients

Alexandre Hainard[1], Xavier Robin[1], Veerle Lejon[2], Daniel Mumba Ngoy[3], Enock Matovu[4], John Enyaru[5], Natalia Tiberti[1], Catherine Fouda[1], M Mueller[6], F Lisacek[6], Natacha Turck[1] and Jean-Charles Sanchez*[1]

Address: [1]Biomedical Proteomics Research Group, Medical and University Centre, Geneva, Switzerland, [2]Department of Parasitology, Institute of Tropical Medicine, Antwerp, Belgium, [3]Institut National de Recherche Biomedicale, Kinshasa, D.R. Congo, [4]Department of Veterinary Parasitology and Microbiology, Faculty of Science, Makerere University, Kampala, Uganda, [5]Department of Biochemistry, Faculty of Science, Makerere University, Kampala, Uganda and [6]Swiss Institute of Bioinformatics, Medical and University Centre, Geneva, Switzerland

Email: Jean-Charles Sanchez* - Jean-Charles.Sanchez@medecine.unige.ch

* Corresponding author

This abstract is available from: http://www.biomedcentral.com/1753-6561/2/S1/P25

Background
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a parasitic tropical disease. It progresses from stage 1 or early phase, when parasites are present in blood and/or lymph, to stage 2 or late stage when parasites have invaded the central nervous system (CNS). As treatment depends on the stage of disease, there is an urgent need for tools that can efficiently discriminate the two stages of HAT. In this context, we hypothesized that markers of brain damage discovered by proteomic strategies as well as cytokines and chemokines could individually or in combination indicate the CNS invasion by the parasite.

Methods
Patients consulting a trypanosomiasis treatment centre in D.R. Congo and infected by *Trypanosoma brucei gambiense* were investigated in this study. They were staged on the basis of the cerebrospinal fluid (CSF) white blood cell count (WBC) and presence of the parasite in CSF. A total of 100 CSF samples, comprising 21 stage 1 (< 5 WBC/µL), 8 intermediate stage (between 5 and 20 WBC/µL) and 71 stage 2 (> 20 WBC/µL), were analysed. CSF concentrations of H-FABP, GSTP-1 and S100β were measured by enzyme-linked immunosorbent assays (ELISA). The levels of thirteen cytokines and chemokines (IL-1ra, IL-1β, IL-6, IL-8, IL-9, IL-10, G-CSF, MIP-1β, VEGF, IFN-γ, MCP-1, TNF-α and IP-10) were determined by bead suspension arrays.

Results
IP-10 was the best individual molecule able to distinguish between stage 1 and stage 2 patients with a sensitivity of 91% and a specificity of 100%. Multivariate analysis defined a panel characterized of GSTP1 (> 5.05 ng/ml), IP-10 (> 2204 pg/ml) and IL-8 (> 102.4 pg/ml), where stage 2 patients were identified with a sensitivity of 97% and a specificity of 100%, when at least one of the 3 molecules is above the cut-off.

Conclusion
This study highlights the value of IP-10 as a single biomarker for staging HAT patients. Its further combination with GSTP1 and IL-8 results in a panel that efficiently identifies stage 2 HAT patients.

Acknowledgements